Stock price performance of Benitec Biopharma Limited is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 71.12% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 36.85% . Looking at the past 52 week period, the stock price is down -25.21% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Benitec Biopharma Limited has a negative value of -10.53 compared to overall market performance. Company shares have received an average consensus rating of Hold for the current week The stock has recorded a 20-day Moving Average of 0.79% and the 50-Day Moving Average is 11.35%.The 200 Day SMA reached 13.99%
Benitec Biopharma Limited is having a Relative Strength Index of 58.53 which indicates the stock is not yet over sold or over bought based on the technical indicators. Benitec Biopharma Limited (NASDAQ:BNTC) has climbed 49.16% in the past week and advanced 66.89% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 48.99% and the outperformance has advanced to 65.4% for the last 4 weeks period.
Benitec Biopharma Limited (NASDAQ:BNTC) stock ended Friday session in the red zone in a volatile trading. The stock closed down 1.08 points or 28.8% at $2.67 with 2,875,063 shares getting traded. Post opening the session at $3.2, the shares hit an intraday low of $2.45 and an intraday high of $3.4 and the price was in this range throughout the day. The company has a market cap of $23 million and the number of outstanding shares has been calculated to be 8,791,745 shares. The 52-week high of Benitec Biopharma Limited (NASDAQ:BNTC) is $4.44 and the 52-week low is $1.2.
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.